Literature DB >> 26830078

Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients.

Chalirmporn Atasilp1, Pichai Chansriwong2, Ekapob Sirachainan2, Thanyanan Reungwetwattana2, Montri Chamnanphon1, Apichaya Puangpetch1, Sansanee Wongwaisayawan3, Chonlaphat Sukasem4.   

Abstract

UDP-glucuronosyltransferase1A1 (UGT1A1) polymorphisms have been related with irinotecan toxicity. The purpose of this study was to determine the associations between UGT1A1(*)28 and (*)6 polymorphisms and irinotecan toxicity in Thai patients with metastatic colorectal cancer. 44 metastatic colorectal cancer patients received irinotecan-based chemotherapy. Hematologic toxicities were determined in the first and second cycles of treatment. The genotypes of UGT1A1(*)28 and (*)6 were analyzed by pyrosequencing technique. The frequencies of genetic testing for UGT1A1(*)28 and (*)6 polymorphisms were 22.8% (TA6/TA7; 20.5%, TA7/TA7; 2.3%) and 15.9% (GA), respectively. No patients had the homozygous UGT1A1(*)6 (AA). Neither UGT1A1(*)28 nor UGT1A1(*)6 polymorphisms were significantly associated with severe hematologic toxicities. However, analysis of UGT1A1(*)28 and (*)6 in combination revealed an association with severe neutropenia in the first and second cycles (P = 0.044, P = 0.017, respectively). Both UGT1A1(*)28 and (*)6 polymorphisms may have an increased risk of irinotecan-induced neutropenia in Thai colorectal cancer patients.
Copyright © 2015 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Irinotecan; Neutropenia; UGT1A1(*)28; UGT1A1(*)6

Mesh：

Substances：

Year:  2015        PMID： 26830078     DOI： 10.1016/j.dmpk.2015.12.004

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN： 1347-4367            Impact factor:   3.614


  12 in total

Review 1.  Uridine 5'-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease.

Authors:  Celia N Sanchez-Dominguez; Hugo L Gallardo-Blanco; Mauricio A Salinas-Santander; Rocio Ortiz-Lopez
Journal:  Exp Ther Med       Date:  2018-05-18       Impact factor: 2.447

2.  Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC/MS/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients.

Authors:  Chalirmporn Atasilp; Pichai Chansriwong; Ekapob Sirachainan; Thanyanan Reungwetwattana; Apichaya Puangpetch; Santirhat Prommas; Suwannee Sirilerttrakul; Budsaba Rerkarmnuaychoke; Sansanee Wongwaisayawan; Chonlaphat Sukasem
Journal:  J Clin Lab Anal       Date:  2017-04-10       Impact factor: 2.352

3.  Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis.

Authors:  Chalirmporn Atasilp; Mohitosh Biswas; Pimonpan Jinda; Nutthan Nuntharadthanaphong; Jiratha Rachanakul; Yaowaluck Hongkaew; Natchaya Vanwong; Surasak Saokaew; Chonlaphat Sukasem
Journal:  Clin Transl Sci       Date:  2022-05-31       Impact factor: 4.438

Review 4.  Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients.

Authors:  Pashtoon Murtaza Kasi; Axel Grothey
Journal:  Drugs       Date:  2018-05       Impact factor: 9.546

5.  Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials.

Authors:  Piera Gargiulo; Laura Arenare; Cesare Gridelli; Alessandro Morabito; Fortunato Ciardiello; Vittorio Gebbia; Paolo Maione; Alessia Spagnuolo; Giuliano Palumbo; Giovanna Esposito; Carminia Maria Della Corte; Floriana Morgillo; Gianfranco Mancuso; Raimondo Di Liello; Adriano Gravina; Clorinda Schettino; Massimo Di Maio; Ciro Gallo; Francesco Perrone; Maria Carmela Piccirillo
Journal:  BMC Cancer       Date:  2021-05-14       Impact factor: 4.430

Review 6.  Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use.

Authors:  Vid Mlakar; Patricia Huezo-Diaz Curtis; Chakradhara Rao Satyanarayana Uppugunduri; Maja Krajinovic; Marc Ansari
Journal:  Int J Mol Sci       Date:  2016-09-08       Impact factor: 5.923

7.  Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy.

Authors:  Yu Bai; Hai-Wei Wu; Xu Ma; Ying Liu; Yan-Hua Zhang
Journal:  Onco Targets Ther       Date:  2017-06-19       Impact factor: 4.147

8.  Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.

Authors:  Dan Liu; Jian Li; Jing Gao; Yanyan Li; Rui Yang; Lin Shen
Journal:  BMC Cancer       Date:  2017-06-20       Impact factor: 4.430

9.  Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy.

Authors:  Xing-Han Liu; Jun Lu; Wei Duan; Zhi-Ming Dai; Meng Wang; Shuai Lin; Peng-Tao Yang; Tian Tian; Kang Liu; Yu-Yao Zhu; Yi Zheng; Qian-Wen Sheng; Zhi-Jun Dai
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

10.  Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy

Authors:  Apatsara Treenert; Nutthada Areepium; Suebpong Tanasanvimon
Journal:  Asian Pac J Cancer Prev       Date:  2018-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.